Mechanism Summary

Exenatide is a 39-amino-acid peptide GLP-1 receptor agonist derived from exendin-4 (originally isolated from Gila monster saliva); it binds and activates the human GLP-1 receptor to enhance glucose-dependent insulin secretion.

Pathways

References

• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53d03c03-ebf7-418d-88a8-533eabd2ee4f
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022200s035lbl.pdf
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d18cfc4-e0de-4814-a712-c1b7c504bff5&audience=consumer
• +7 more

Notes

Expansion-batch evidence packet requires human review before publication. | CAS number, UNII, RxNorm, and ChEMBL identifiers remain unresolved (PubChem full record required JavaScript rendering and is disallowed by robots.txt for this session's fetch tool; DrugBank gates the CAS/UNII fields; NIH GSRS host was blocked at the network layer this session) -- open ops-level gap, not a claim-level defect. | RESOLVED 2026-08-29: EXSCEL trial safety-detail claim (exenatide-adverse-effect-exscel-safety-001) was unresolved at independent review because NEJM and PMC full text were CAPTCHA/403-blocked. This pass pulled the sponsor-posted ClinicalTrials.gov results record for the same trial (NCT01144338), a structured-database primary-results family, and it independently confirms the packet's pancreatitis/pancreatic-malignancy/MTC/heart-failure comparisons. Claim and reviewFlags updated; promotion blocker cleared. | RESOLVED 2026-08-29: exenatide-approved-indication-001 promotion blocker (missing discontinued-market disclosure) addressed by adding a note, sourced to UHCprovider's Oct. 2024 discontinuation bulletin, that AstraZeneca discontinued Byetta (Oct. 25, 2024) and Bydureon BCise (Oct. 28, 2024) for commercial reasons; underlying FDA approval/labeling is unaffected. | Weight-loss-marketing evidence-gap claim rests on a single lower-authority fact-check source; seek an independent corroborating source (e.g., FDA consumer update or a peer-reviewed comparative review) at review time. | exenatide-dose-context-byetta-001 independent corroboration (RxList) largely republishes FDA label text rather than being a materially independent verification family; no controlled-study or clinical-guideline family source was reached within this session's budget to independently corroborate the specific titration schedule -- open, low-risk gap. | Compiled draft requires human review before publication.